A US-based medical device innovator focused on endovascular solutions for neurology and radiology markets that recently achieved revenue growth to $33.6M despite ongoing net losses.
The company demonstrates a clear revenue growth trajectory with a 23% increase over the last two years while narrowing its net loss significantly year-over-year, suggesting improving operational efficiency. With substantial R&D investments in endovascular technologies and a manageable asset base of only $27.2M total assets, there is potential for rapid scaling if new product launches succeed. The specialized nature of its neurology-focused portfolio creates a niche market position that larger competitors may find difficult to penetrate quickly.
KORU Medical operates with a substantial accumulated deficit of $-29.4M and continues to burn cash, evidenced by negative operating cash flow of $319k and net change in cash of $-1.9M. The company's high operating expenses of $27.8M against revenue of $33.6M leaves a thin gross margin environment that is vulnerable to supply chain disruptions or pricing pressure. Investors face significant uncertainty regarding the timeline to achieve sustainable profitability given the heavy investment in R&D and administrative costs without corresponding bottom-line improvement.
KORU Medical Systems is a medical device manufacturer specializing in endovascular tools and solutions primarily serving neurologists and interventional radiologists in the United States. The company focuses on developing catheter-based technologies designed to simplify complex procedures, with its portfolio including products for stroke intervention and peripheral vascular disease treatment. Operating within the competitive medical technology sector, the firm aims to improve patient outcomes through innovative engineering while managing a lean operational cost structure.
While revenue increased to $33.6M in 2024 compared to $27.9M two years prior, the company continues to report a net loss, though it improved from $-13.7M in 2023 to $-6.1M last year. The positive change in accounts payable and inventory management helped offset higher general and administrative expenses of $21.6M, indicating disciplined cost control despite the shrinking cash balance which ended at $9.6M.
The global medical device industry for endovascular products is valued at tens of billions with steady double-digit growth driven by aging populations and increasing prevalence of vascular diseases. However, the sector faces intense competition from established giants like Boston Scientific and Medtronic who dominate market share through economies of scale and extensive distribution networks. Regulatory hurdles such as FDA approval processes and stringent reimbursement policies remain critical barriers to entry and ongoing operational costs for all participants.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $27.9M | $28.5M | $33.6M |
| Cost of Revenue | $12.5M | $11.8M | $12.3M |
| Gross Profit | $15.4M | $16.7M | $21.3M |
| Operating Expenses | $26.1M | $27.0M | $27.8M |
| Operating Income | $-10.8M | $-10.3M | $-6.4M |
| R&D | $5.0M | $5.7M | $5.3M |
| G&A | $20.6M | $20.4M | $21.6M |
| Stock-Based Comp | $3.1M | $2.8M | $2.6M |
| D&A | $587.1K | $870.4K | $888.5K |
| Other OpEx | $587.1K | $870.4K | $888.5K |
| Non-Operating Income | $105.7K | $496.4K | $382.5K |
| Pre-Tax Income | $-10.7M | $-9.8M | $-6.1M |
| Income Tax | $-2.0M | $4.0M | $2.9K |
| Continuing Ops | $-8.7M | $-13.7M | $-6.1M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-8.7M | $-13.7M | $-6.1M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-8.7M | $-13.7M | $-6.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $29.8M | $20.3M | $19.1M |
| Cash & Equivalents | $17.4M | $11.5M | $9.6M |
| Accounts Receivable | $3.6M | $4.0M | $5.7M |
| Inventory | $6.4M | $3.5M | $2.8M |
| Other Current Assets | $2.4M | $1.2M | $1.0M |
| Long-Term Assets | $12.5M | $8.2M | $8.1M |
| PP&E (Net) | $3.9M | $3.8M | $4.3M |
| Operating Leases | $3.8M | $3.5M | $3.0M |
| Other LT Assets | $4.9M | $853.3K | $829.2K |
| Total Assets | $42.3M | $28.5M | $27.2M |
| Current Liabilities | $7.0M | $4.5M | $7.2M |
| Accounts Payable | $2.4M | $975.2K | $1.6M |
| Current Leases | $345.8K | $368.3K | $400.3K |
| Other Current Liab | $1.3M | $1.4M | $1.2M |
| Long-Term Liabilities | $4.0M | $3.7M | $3.2M |
| LT Operating Leases | $3.7M | $3.3M | $3.0M |
| Other LT Liab | $394.3K | $316.6K | $202.6K |
| Total Liabilities | $11.0M | $8.1M | $10.4M |
| Shareholders' Equity | $31.3M | $20.4M | $16.8M |
| Retained Earnings | $-9.6M | $-23.3M | $-29.4M |
| Treasury Stock | $3.8M | $3.8M | $3.9M |
| Total L&E | $42.3M | $28.5M | $27.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-8.7M | $-13.7M | $-6.1M |
| Non-Cash Adjustments | $873.0K | $14.9M | $2.2M |
| Working Capital Changes | $2.4M | $-6.0M | $3.5M |
| Cash from Operations | $-5.4M | $-4.9M | $-319.7K |
| Cash from Investing | $-2.8M | $-814.6K | $-1.3M |
| Cash from Financing | $279.5K | $-218.9K | $-248.5K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-7.9M | $-5.9M | $-1.9M |
| Beginning Cash | $25.3M | $17.4M | $11.5M |
| Ending Cash | $17.4M | $11.5M | $9.6M |
Endovascular Interventional Products targeting stroke and vascular disease markets, General Surgical Instrumentation for broader procedural applications, and Emerging Technologies or Research & Development initiatives supporting future pipeline expansion.
Persistent operating losses of $6.1M impacting retained earnings and raising questions about path to profitability, reliance on a concentrated set of medical device customers and payers susceptible to regulatory changes, and the ongoing need for significant R&D spending of $5.3M without guaranteed commercial returns, plus potential patent challenges from larger competitors.
Specialized intellectual property in catheter delivery systems that reduce procedural complexity for clinicians, a highly focused product portfolio with lower capital expenditure requirements compared to large-scale hardware manufacturers, and strong relationships with key neurology and radiology physician networks.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.